Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
1. An antibody which binds to human CD37 comprising:
(a) a variable heavy chain (VH) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a variable light chain (VL) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 27, the sequence YAS, and SEQ ID NO: 31, respectively, or
(b) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 20, the sequence KAS, and SEQ ID NO: 21, respectively.
2. The antibody of claim 1 , which comprises the VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and the VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 27, the sequence YAS, and SEQ ID NO: 31, respectively.
3. The antibody of claim 1 , which comprises the VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and the VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 20, the sequence KAS, and SEQ ID NO: 21, respectively.
4. The antibody of claim 2 , which comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 22 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 29.
5. The antibody of claim 3 , which comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 15 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 19.
6. The antibody of claim 2 , which comprises a human IgG1 heavy chain constant region.
7. The antibody of claim 3 , which comprises a human IgG1 heavy chain constant region.
8. The antibody of claim 6 , wherein the human IgG1 heavy chain constant region comprises a substitution of glutamic acid at position 430 for glycine, and wherein the amino acid residue is numbered according to the EU Index.
9. The antibody of claim 7 , wherein the human IgG1 heavy chain constant region comprises a substitution of glutamic acid at position 430 for glycine, and wherein the amino acid residue is numbered according to the EU Index.
10. The antibody of claim 2 , which comprises a kappa light chain constant region.
11. The antibody of claim 3 , which comprises a kappa light chain constant region.
12. A bispecific antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises a first antigen-binding region and the second binding arm comprises a second antigen-binding region, wherein both the first antigen-binding region and second antigen-binding region bind to human CD37, and wherein
(a) the first antigen-binding region comprises a variable heavy chain (VH) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a variable light chain (VL) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 27, the sequence YAS, and SEQ ID NO: 31, respectively, and
(b) the second antigen-binding region comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 20, the sequence KAS, and SEQ ID NO: 21.
13. The bispecific antibody of claim 12 , wherein:
(a) the first antigen-binding region comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 22 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 29, and
(b) the second antigen-binding region comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 15 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 19.
14. The bispecific antibody of claim 13 , wherein the first binding arm comprises a first human IgG1 heavy chain constant region and the second binding arm comprises a second human IgG1 heavy chain constant region.
15. The bispecific antibody of claim 14 , wherein both the first and second human IgG1 heavy chain constant regions comprise a substitution of glutamic acid at position 430 for glycine, and wherein the amino acid residue is numbered according to the EU Index.
16. The bispecific antibody of claim 14 , wherein the first human IgG1 heavy chain constant region comprises a substitution of phenylalanine at position 405 for leucine, wherein the second human IgG1 heavy chain constant region comprises a substitution of lysine at position 409 for arginine, and wherein the amino acid residues are numbered according to the EU Index.
17. The bispecific antibody of claim 14 , wherein the first human IgG1 heavy chain constant region comprises a substitution of lysine at position 409 for arginine, wherein the second human IgG1 heavy chain constant region comprises a substitution of phenylalanine at position 405 for leucine, and wherein the amino acid residues are numbered according to the EU Index.
18. The bispecific antibody of claim 13 , wherein both the first binding arm and second binding arm comprise a human kappa light chain constant region.
19. A bispecific antibody comprising a first binding arm comprising a first heavy chain and a first light chain and a second binding arm comprising a second heavy chain and a second light chain, wherein both the first binding arm and second binding arm bind to human CD37, and wherein:
(a) the first heavy chain comprises a variable heavy chain (VH) region comprising the amino acid sequence set forth in SEQ ID NO: 22, and the first light chain comprises a variable light chain (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 29, and
(b) the second heavy chain comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 15, and the second light chain comprises a VL region comprising the amino acid sequence set forth in SEQ ID NO: 19,
wherein the first heavy chain and second heavy chain comprise heavy chain constant regions comprising the amino acid sequences set forth in SEQ ID NOs: 59 and 60, respectively, and
wherein both the first light chain and second light chain comprise a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 61.
20. A bispecific antibody comprising a first binding arm comprising a first heavy chain and a first light chain and a second binding arm comprising a second heavy chain and a second light chain, wherein both the first binding arm and second binding arm bind to human CD37, and wherein:
(a) the first heavy chain comprises a variable heavy chain (VH) region comprising the amino acid sequence set forth in SEQ ID NO: 22, and the first light chain comprises a variable light chain (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 29, and
(b) the second heavy chain comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 15, and the second light chain comprises a VL region comprising the amino acid sequence set forth in SEQ ID NO: 19,
wherein the first heavy chain and second heavy chain comprise heavy chain constant regions comprising the amino acid sequences set forth in SEQ ID NOs: 60 and 59, respectively, and
wherein both the first light chain and second light chain comprise a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 61.